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Introduction

35
Enterovirus 71 (EV71) and Coxsackievirus A16 (CVA16) are structurally similar viruses 36 belonging to Enterovirus genus of the Picornaviridae family [1] . EV71 and CVA16 are non-37 enveloped single-stranded RNA viruses, the causative agents of hand, foot, and mouth disease 38 (HFMD) in children. Enteroviruses could cause severe neurological complications that can 39 potentially be fatal. The large outbreaks of HFMD in Asia-Pacific regions and the lack of 40 therapeutics or preventive vaccines against HFMD is a major public health concern [2, 3] . 41
Moreover, co-circulation and co-infection by both EV71 and CVA16 viruses resulting in 42 elevated numbers of HFMD infections were reported in China [4] . It was also reported that 43 individuals vaccinated with EV71 vaccine candidate could still develop HFMD through CVA16 44 infection [5] , confirming that a monovalent EV71 vaccine is not cross protective against CVA16. 45
Hence, an effective bivalent vaccine against both viruses is needed to prevent HFMD. 46
Virus-like particle (VLP) vaccines have a proven track record on safety and efficacy, given the 47
Materials and methods
81
Construction of transfer vectors 82
Human EV71 (SB12736-SAR-03) and CVA16 (SB3512/SAR/00) VLP cassettes (P1-EMCV 83 IRES-3CD) were synthesized by DNA2.0 and subcloned into the Gateway® destination vector 84 pDEST TM 8 by attL/attR in vitro recombination using LR Clonase® from Life Technologies 85 (CA, USA). 86
Cells and virus 87
Spodoptera frugiperda (Sf9) and Trichoplusia ni (High Five TM ) insect cell lines were cultured in 88
Sf-900 TM II serum-free media (SFM) (Life Technologies). Cells were maintained in suspension 89 at mid-log phase and incubated at 27 o C in a shaking incubator set at 120 rpm. and the cell density and viability were monitored using a Countess® automated cell counter (Life 104 Technologies) using the 0.2% trypan blue exclusion method. Passage 2 BV stock was harvested 105 from the culture by centrifugation at 1,500 x g for 5 min to remove cells. Virus titers of BV 106 stocks were estimated based on the viable cell size method [17] . 107
Expression Screen 108
Passage 4 expression was set up with both Sf9 and High Five TM cells cultured in Sf-900 TM II 109 SFM at mid-log phase (3 x 10 6 cells/mL and 1.5 x 10 6 cells/mL, respectively). The cells were 110 infected with passage 3 BV stocks at an estimated MOI of 5. The cultures were incubated at 111 27°C or 21°C in a shaking incubator set at 120 rpm. Cell densities and viabilities were monitored 112 as described above. Both cells and supernatant were collected every 24 h for Western blot 113 analysis. 114
Serial Passaging 115
Budded virus was continuously serial passaged up to passage 8 to obtain BV stocks for Expression culture was harvested by centrifugation at 8,000 x g for 20 min and the cells and 127 supernatants were collected separately for purification. The cell pellet was resuspended in lysis 128 buffer (20 mM NaH 2 PO 4 , 500 mM NaCl, pH 7.5) and disrupted using a Sonifer® Cell Disrupter 129 with a 1/2" titanium horn (Branson® Ultrasonics, NC, USA). Cell debris was removed by 130 centrifugation at 15,000 x g for 30 min. VLPs in the clarified soluble fraction were recovered by 131 ammonium sulphate ((NH 4 ) 2 SO 4 ) precipitation at 20% saturation for 30 min at room 132 temperature. The precipitated VLPs were pelleted by centrifugation at 10,000 x g for 10 min and 133 resuspended in 20 mM Tris, 50 mM NaCl, pH 7.5 before loading onto a Capto™ Core 700 134 column (CV 4.7 mL) (GE Healthcare Life Sciences, Uppsala, Sweden) at 1 mL/min flow rate in 135 a flow-through mode purification. 136
For purification of VLPs from the extracellular fraction, culture supernatant was first filtered 137 using a 0.45 μm filter. The filtered supernatant was 10 times concentrated with a tangential flow 138 filtration (TFF) unit with a 300 kDa nominal molecular weight cut-off (MWCO) ultrafiltration 139 cassette (Sartorius AG, Goettingen, Germany) and buffer exchanged into 20 mM Tris, 50 mM 140 NaCl, pH 7.5. The retentate material was centrifuged at 16,500 x g for 15 min at 4 o C to remove 141 particulates before being loaded onto a Capto™ Core 700 column (CV 4.7 mL) in a flow-142 through mode purification at 1 mL/min flow rate. 143
Western blot analysis 144
The VLP samples were analyzed on a 12% SDS-polyacrylamide gel electrophoresis (PAGE) 145 under reduced and denatured conditions. The SDS-PAGE gel was transferred onto PVDF 146 membrane using iBlot® Western blotting system (Life Technologies) and probed with the8 CVA16 VP1, rabbit anti-EV71-VP0 polyclonal sera or rabbit anti-CVA16-VP0 polyclonal sera) 149 at a dilution of 1:4,000 and followed by the secondary antibody (HRP-conjugated goat anti-150 rabbit IgG) at a dilution of 1:15,000. Chemiluminescent signals were developed using ECL 151 chemiluminescent substrate reagent kit (Life Technologies) and visualized on a Chemi-Doc TM 152 XRS+ imaging system (Bio-Rad Laboratories, Inc., CA, USA). 153
Asymmetric flow field-flow fractionation analysis 154
Asymmetric flow field-flow fractionation (AF4) analysis was performed as per previously 155 described [18] , with some modifications. Briefly, the injected samples were focused for 6 min at 156 the marrow injection point. The detector flow through the downstream of detectors was 157 maintained at 1.2 mL/min. At the end of the focus mode, the analytes were eluted under a 158 constant cross flow of 1 mL/min for 30 min, after which the cross flow rate was decreased 159 stepwise to zero for the elution of highly retained analytes. The AF4 analysis was performed 160 using an Eclipse® 3+ system (Wyatt Technology Corporation, CA, USA) coupled with SPD-161 20A UV/Vis detector (Shimadzu, Kyoto, Japan) and a DAWN Heleos II multi-angle light 162 scattering detector (MALS, Wyatt Technology Corporation). The AF4 system was equilibrated 163 with 50 mM Tris-Glycine, 150 mM NaCl, pH 7.4 prior to analysis. VLP samples were 164 centrifuged (16,500 x g, 4°C, 15 min), and 100 μL of the supernatant was injected into AF4 and 165 fractionated. Data acquisition and analysis were formed using the Astra® V software (Version 166
5.3, Wyatt Technology Corporation). Immunoaffinity chromatography purified EV71 VLPs 167
(supplied by Sentinext Therapeutics) was used as a standard for initial AF4 method development. 168
Transmission electron microscopy analysis 169
Transmission electron microscopy (TEM) was performed using 5 μL of purified VLP sample 170 applied to a Formvar coated, 200-mesh copper grid, rinsed with water, and stained with 1% w/v9 uranyl acetate. Sample grids were analyzed with a JEOL 1010 (JEOL, Tokyo, Japan) microscope 172 at 100 kV and the electron micrographs were recorded using a Morada camera (Olympus® Soft 173
Imaging System GmbH). 174
Results and discussion
175
Effect of temperature and cell line 176
The expression of EV71 and CVA16 was tested in two commonly used insect cell lines, Sf9 and 177
High Five™, and at incubation temperatures of either 21°C or 27°C. Both cells and supernatant 178
were collected every 24 h for the detection of viral structural proteins. Figure 2A They also showed higher yields in Sf9 cells than in High Five TM cells and suggested that this 217 could be due to the cellular and genetic differences of the two cell lines [20] . 218
The baculovirus-insect cell system is a powerful system for recombinant protein expression [21] . 219
However, as a lytic viral expression system, cell lysis-associated proteolysis is a major drawback 220
[22]. Culture temperature and pH are key factors that can influence proteolytic activity and 221 product quality in the baculovirus-insect cell system [23] . Previous studies have shown that 222 lowering the incubation temperatures from 28°C or 30°C to 20°C increased recombinant protein 223 production yield in insect cells [24, 25] . Rapid depletion of oxygen in cultures was observed at 224 elevated temperatures [26] . Such increases in the respiratory and metabolic activity at elevated 225 temperatures often increases the rate of cell death and terminates recombinant protein production 226
[27]. Premature termination of P1 polyprotein and/or 3CD protease production at high 227 temperature would affect P1 polyprotein processing into structural proteins (VP0, VP3 and VP1), 228 a pre-requisite to spontaneous VLP assembly. Production of VLPs using the baculovirus-insect 229 cell system at 21°C may have slowed down cell metabolic activity, thus delaying cell lysis and 230 prolonging the life span of infected cells to allow structural protein processing and maturation of 231 VLPs in the cells. 232
Effect of serial passaging on expression 233
The effect of serial passaging BV stocks on the production of EV71 and CVA16 VLPs was 234 investigated in Sf9 cells at 27°C. Structural protein production analyzed on Western blots probed 235 with anti-EV71-VP1 antibody ( Figure 3A) indicated that there was a significant drop in CVA16 236 VP1 production after 5 passages of BV stocks in cell culture. In contrast, EV71 VP1 production 237 was detected for at least 9 passages, although a gradual decrease in VP1 production was12 observed. The cell densities and viabilities post infection of all cultures at each passage were 239 determined and no significant difference was observed ( Figure 3B ). The titers of BV stocks did 240 not decline with increasing passage number (Table 1) infection. This in turn results in a decrease in recombinant protein production [29, 30] . 246
Accumulation of DIPs without either or both P1 and 3CD protease genes during the serial 247 passaging of BV stocks for scale-up production could render this VLP production process 248 unviable if it is not carefully monitored. 249
Effect of virus stock storage on expression 250
The effect storage stability at 4°C of passage 3 BV stock on the structural protein production of 251 both EV71 and CVA16 constructs was investigated ( Figures 4A and 4B ). EV71 and CVA16 252 structural protein production was analyzed by Western blots, using anti-EV71-VP0 and anti-253 CVA16-VP0 antibodies, respectively. EV71 passage 3 BV stock retained its ability to infect Sf9 254 cells leading to comparable structural protein production ( Figure 4A ) after storage for 4 months 255 at 4°C. However, a significant reduction in the CVA16 structural protein production was 256 observed for BV stock stored at 4°C for 4 months ( Figure 4B ). Given the sensitivity of CAV16 257 passage 3 BV virus stock to storage at 4°C, freshly amplified passage 3 BV stock from passage 2 258 BV stock should be used for each production run. Figure 4C shows that CVA16 passage 2 BV 259 stock maintained better infectivity, thus productivity, when stored at -80°C than at 4°C ( Figure4C ). The freeze-thaw effect on BV infectivity could have caused the slight decrease in structural 261
proteins, similar to a previous report [31] . 
Characterization of EV71 and CVA16 VLPs 296
The first use of AF4-MALS technique for accurately characterizing EV71 and CVA16 VLPs is 297 demonstrated here ( Figures 5C and 5D ). The AF4-MALS method for enterovirus VLP 298 characterization was developed and optimized using EV71 VLP standard, based on a previously 299 described method [18] . A VLP peak was detected at a retention time of 20 min, and the average 300 root mean square (rms) radius of EV71 VLP standard was calculated as 15.4 ± 1 nm. A peak at a 301 retention time of 12 min (likely comprised of proteins) and an aggregate peak at a retention time 302 greater than 40 min were also observed. This AF4-MALS analytical method was used to 303 characterize the size and distribution of purified VLPs of EV71 ( Figure 5C ) and CVA16 (Figure  304   5D ). The average rms radius of EV71 and CVA16 VLPs were calculated as 15 ± 1 nm and 15.3 305 ± 5.8 nm, respectively. As illustrated in Figures 5C and 5D , the heterogeneity of VLP samples 306 could be detected and characterized using AF4-MALS. The VLP yields calculated from the VLP 307 peak areas (Peak B) reveal that EV71 VLP yield is 2.7x higher than CVA16. This method allows 308 quantitative characterization of VLPs in parallel to VLP visualization under TEM ( Figure 5E ). 309
The size measurement of both EV71 and CVA16 VLPs by AF4-MALS is consistent with 310 reported measurements using dynamic light scattering (30 nm diameter) [37] . Unlike the 311 dynamic light scattering method, AF4-MALS technique allows high resolution of particles based 
Conclusions
